



Crescendo Biologics to Present Poster at AACR Annual Meeting 18 April 2018

Cambridge, UK, 20 March 2018 – Crescendo Biologics Limited (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, announces that Dr Brian McGuinness, Head of New Product and Business Development, Phil Bland-Ward (CSO) and James Legg (VP R&D) will be presenting a poster at AACR (American Association for Cancer Research) Annual Meeting in Chicago, USA on 18 April 2018.

The Crescendo team will be available to discuss the poster entitled “*Multifunctional biologics for targeted T-cell therapy based on in vivo matured fully human VH domains*” within the “Antibodies, Fusion Proteins and Related Biologics session”. This will cover the beneficial characteristics of Humabodies and their enhanced therapeutic potential over traditional monoclonal antibodies.

Poster details

Title: Multifunctional biologics for targeted T-cell therapy based on in vivo matured fully human VH domains

Authors: J. Legg, B. McGuinness, P. Bland-Ward, P. Pack

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibodies, Fusion Proteins, and Related Biologics

Session Date and Time: Wednesday Apr 18, 2018 8:00 AM - 12:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 11

Permanent Abstract Number: 5766

There will also be a poster by Eleven Biotherapeutics in the same session which includes data from Crescendo. This poster, entitled ‘*Engineering and characterization of anti-PSMA humabody-deBouganin fusion proteins*’, will be at Board Number 15.

AACR’s Annual Meeting is being held in Chicago, Illinois from 14 – 18 April. The theme is ‘Driving Innovative Cancer Science to Patient Care’. Presentations at the Annual Meeting will cover the latest basic, translational, clinical, and prevention-focused research in the field, including important areas such as early detection, cancer interception, and survivorship in all populations.

Ends

For more information, please contact:

Crescendo Biologics Dr Peter Pack, CEO	Tel: 44 (0)1223 497140 info@crescendobiologics.com
---	---



Instinctif Partners Deborah Bell / Dr Christelle Kerouedan	Tel: 44 (0)20 7457 2020 crescendo@instinctif.com
--	--

Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody[®] therapeutics in oncology, with an internal focus on biologics for Targeted T-cell Therapy with novel modes-of-action. It is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships, in both multi-functional immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform, generating 100% human V_H domain building blocks (Humabody[®] V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com